Bottom line
What is PMVAX's expense ratio?
PMVAX's expense ratio is 1.02%, or about $102 a year on every $10,000 invested. That is more expensive than 65% of large blend funds we track (median 0.83%). This share class also charges a front-end sales load of up to 5.75%, taken from your investment when you buy. Its expense ratio includes a 0.25% 12b-1 marketing fee.
Updated Aug 25, 2025
PMVAX fee table
| Net expense ratio | 1.02% |
|---|---|
| Gross expense ratio | 1.02% |
| Management fee | 0.54% |
| 12b-1 (distribution) fee | 0.25% |
| Other expenses | 0.23% |
| Max front-end sales load | 5.75% |
| Max deferred sales charge | 1% |
Source: Fund prospectus fee table, filed Aug 25, 2025
What PMVAX costs in dollars
The SEC requires every fund to show what a $10,000 investment would cost, assuming 5% annual returns and that you sell at the end of each period:
| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| PMVAX | $673 | $881 | $1,106 | $1,751 |
Source: Fund prospectus expense example
The long-run cost of fees
On $100,000 growing at 6% a year for 20 years, a 1.02% expense ratio costs roughly $56,400 in lost growth, versus about $46,700 for the median large blend fund (0.83%).